Baxter International Inc 

BAX:NYSE

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
73.02 0.21   0.29%2.68%2,842,4862.5M

Market data is delayed by at least 20 minutes.
Market is closed. As of 03:59 PM ET 7/26/2013
 
 
 

Latest News Headlines for Baxter International Inc

Baxter Declares Quarterly Dividend
3 days 15 hours 19 minutes ago - BusinessWire via Dow Jones News
DEERFIELD, Ill.--(BUSINESS WIRE)--July 23, 2013-- The Board of Directors of Baxter International Inc. (NYSE:BAX) today declared a quarterly dividend of $0.49 per Baxter common share. The dividend is payable on October 1, 2013 to shareholders of record as of September 6, 2013.
Increased Demand, Fast Track Designations, and Strong Sales Boost Revenue Growth - Research Report on Alexion, Baxter International, Align Technology, Transition, and OPKO
3 days 23 hours 48 minutes ago - PR Newswire via Dow Jones News
Editor Note: For more information about this release, please scroll to bottom NEW YORK, July 23, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Baxter International Inc. (NYSE: BAX), Align Technology, Inc. (NASDAQ: ALGN), Transition Therapeutics Inc. (NASDAQ: TTHI), and OPKO Health Inc. (NYSE: OPK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
European Medicines Agency Approves SmPC Change to Baxter's ADVATE to Include Information on PK-Guided Dosing Study
4 days 22 hours 49 minutes ago - BusinessWire via Dow Jones News
Personalized, PK-Guided Dosing Shown to be as Effective as Standard Prophylaxis in Reducing Annual Bleeding Rate for Hemophilia A Patients LONDON--(BUSINESS WIRE)--July 22, 2013-- Baxter International Inc. (NYSE:BAX) today announced that the European Medicines Agency has authorized an update to the Summary of Product Characteristics (SmPC) for Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin Free Method, (in the EU, ADVATE, octocog alfa)] to include findings of the Phase IV prophylaxis study.
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 21, 2013
This report contains detailed information about the company's business finances and management.
10-Q
May 1, 2013
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Baxter International Inc. (Baxter) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company operated in two segments: BioScience and Medication Delivery. It is engaged in the medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. In February 2012, it acquired Synovis Life Technologies, Inc. In November 2011, it acquired Baxa Corporation. In April 2012, it purchased SIGMA International General Medical Apparatus, LLC.

Bid/Size
-- / --
Ask/Size
-- / --
Price Open
72.83
Previous Close
72.81
Day High
73.42
Day Low
72.4099
52wk High/Date
74.60 / 7/23/2013
52wk Low/Date
56.95 / 7/26/2012
% off 52wk High
-2.12%
% off 52wk Low
28.22%
Beta (5 Yr)
0.6
Market Capitalization
39.6B
Shares Outstanding
542.0M
Volatility Avg
16.18
EPS(TTM)
4.02
P/E Ratio
18.2x
Dividend Announcement
7/23/2013
Dividend Yield
2.68%
Ex-Date
9/4/2013
Date of Record
9/6/2013
Payable
0.49 - QRTR
Payable Date
10/1/2013
Last Trade as of 7/26/2013 4:00 PM ET
 
 
 

BAX Baxter International Inc vs. Peers

Peers 
BAX
Baxter International Inc
9.54%
Boston Scientific Corporation
91.27%
Johnson & Johnson
32.43%
Abbott Laboratories
17.36%
BAX
Baxter International Inc
2.68%
Boston Scientific Corporation
--
Johnson & Johnson
2.84%
Abbott Laboratories
1.52%
BAX
Baxter International Inc
0.29%
Boston Scientific Corporation
1.20%
Johnson & Johnson
0.28%
Abbott Laboratories
0.55%
Compare these stocks